Nontuberculous mycobacteria (NTM) are troublesome pathogens that can cause significant pulmonary disease in patients with cystic fibrosis (CF). Diagnosis can be difficult in the setting of underlying CF and treatment regimens are burdensome on both patients and providers. Recent consensus guidelines for treatment of NTM in CF have provided a guide for the CF community, however research is lagging regarding accuracy of our diagnostic abilities and treatment efficacy. In this review, we provide new insights into the complexity of NTM from emerging whole genome sequencing data, a summary of current NTM diagnosis and treatment guidelines, highlight new treatment options, and discuss future research projects which aim to better define which patients to treat and timing and duration of treatment.
CITATION STYLE
Martiniano, S. L., Davidson, R. M., & Nick, J. A. (2017, November 1). Nontuberculous mycobacteria in cystic fibrosis: Updates and the path forward. Pediatric Pulmonology. John Wiley and Sons Inc. https://doi.org/10.1002/ppul.23825
Mendeley helps you to discover research relevant for your work.